Circulating neuregulin during the transition from stage a to stage B/C heart failure in a breast cancer cohort

Journal of Cardiac Failure

Volumn 19, Issue 1, 2013, Pages 10-15

  Geisberg, Carrie A ^a,c   Abdallah, Wissam M ^a   Da Silva, Monica ^a   Silverstein, Cheri ^b   Smith, Holly M ^a   Abramson, Vandana ^a   Mayer, Ingrid ^a   Means Powell, Julie ^a   Freehardt, Darla ^a   White, Brenda ^a   Lenihan, Daniel ^a   Sawyer, Douglas B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Cardiac function; cardio oncology; cardiotoxicity; neuregulin

Indexed keywords

ANTHRACYCLINE; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; COHORT ANALYSIS; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUREGULINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; STROKE VOLUME; SURVIVAL RATE;

EID: 84871853849     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.11.006     Document Type: Article

References (27)

1. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, and T.G. Ganiats ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 112 2005 e154 e235
2. L.C. Kremer, H.J. van der Pal, M. Offringa, E.C. van Dalen, and P.A. Voute Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review Ann Oncol 13 2002 819 829
3. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, and T.G. Ganiats 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 90
4. B. Ky, S.E. Kimmel, R.N. Safa, M.E. Putt, N.K. Sweitzer, and J.C. Fang Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure Circulation 120 2009 310 317
5. C.A. Geisberg, G. Wang, R.N. Safa, H.M. Smith, B. Anderson, and X.-Y. Peng Circulating neuregulin-1 beta levels vary according to the angiographic severity of coronary artery disease and ischemia Coronary artery disease 22 2011 577 582
6. L.W. Jones, M.J. Haykowsky, J.J. Swartz, P.S. Douglas, and J.R. Mackey Early breast cancer therapy and cardiovascular injury J Am Coll Cardiol 50 2007 1435 1441
7. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
8. A.L. Stewart, K.M. Mills, A.C. King, W.L. Haskell, D. Gillis, and P.L. Ritter CHAMPS physical activity questionnaire for older adults: outcomes for interventions Med Sci Sports Exerc 33 2001 1126 1141
9. I.M. Lee, L. Djousse, H.D. Sesso, L. Wang, and J.E. Buring Physical activity and weight gain prevention JAMA 303 2010 1173 1179
10. C.A. Geisberg, and D.J. Lenihan Neuregulin in heart failure: reverse translation from cancer cardiotoxicity to new heart failure therapy Herz 36 2011 306 310
11. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
12. N. Benac More cancer survivor planning urged CMAJ 183 2011 E468
13. E. Tan-Chiu, G. Yothers, E. Romond, C.E. Geyer Jr., M. Ewer, and D. Keefe Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 2005 7811 7819
14. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer Jr., and N.E. Davidson Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
15. D.D. von Hoff, M.W. Layard, P. Basa, H.L. Davis Jr., A.L. von Hoff, and M. Rozencweig Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
16. G. Curigliano, E.L. Mayer, H.J. Burstein, E.P. Winer, and A. Goldhirsch Cardiac toxicity from systemic cancer therapy: a comprehensive review Prog Cardiovasc Dis 53 2010 94 104
17. I.C. Henderson, D.A. Berry, G.D. Demetri, C.T. Cirrincione, L.J. Goldstein, and S. Martino Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 2003 976 983
18. E.A. Perez, V.J. Suman, N.E. Davidson, P.A. Kaufman, S. Martino, and S.R. Dakhil Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial J Clin Oncol 22 2004 3700 3704
19. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
20. D. Cardinale, M.T. Sandri, A. Martinoni, E. Borghini, M. Civelli, and G. Lamantia Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy Ann Oncol 13 2002 710 715
21. D. Cardinale, M.T. Sandri, A. Colombo, N. Colombo, M. Boeri, and G. Lamantia Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754
22. A. Tragiannidis, C. Dokos, V. Tsotoulidou, A. Giannopoulos, Z.D. Pana, and T. Papageorgiou Brain natriuretic peptide as a cardiotoxicity biomarker in children with hematological malignancies Minerva Pediatr 64 2012 307 312
23. L.M. Sherief, A.G. Kamal, E.A. Khalek, N.M. Kamal, A.A. Soliman, and A.M. Esh Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children Hematology 17 2012 151 156
24. X. Liu, X. Gu, Z. Li, X. Li, H. Li, and J. Chang Neuregulin-1/ErbB- activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy J Am Coll Cardiol 48 2006 1438 1447
25. B. Ky, S.E. Kimmel, R. Safa, M.E. Putt, N.K. Sweitzer, and J.C. Fang Association between circulating neuregulin-1 beta and clinical outcomes in heart failure J Am Coll Cardiol 53 2009 A175-A
26. C.A. Geisberg, G. Wang, R.N. Safa, H.M. Smith, B. Anderson, and X.Y. Peng Circulating neuregulin-1beta levels vary according to the angiographic severity of coronary artery disease and ischemia Coron Artery Dis 22 2011 577 582
27. J.L. Patnaik, T. Byers, C. DiGuiseppi, D. Dabelea, and T.D. Denberg Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study Breast Cancer Res 13 2011 R64